Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib as induction therapy in stage IIIA-N2 NSCLC
NCT00600587Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Started Sep 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00600587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600587.